Abstract
Botulinum neurotoxin type B (BT, BT-B) has been used as NeuroBloc®/MyoBloc™ since 1999 for treatment of cervical dystonia, hyperhidrosis, spastic conditions, cerebral palsy, hemifacial spasm, bladder dysfunction, spasmodic dysphonia, sialorrhoea, anal fissures, piriformis syndrome, various pain conditions and cosmetic applications. Generally, its therapeutic effects are comparable to BT type A (BT-A). The adverse effect profiles of BT-B and BT-A, however, differ considerably. BT-B has been found to produce more regional as well as systemic anticholinergic adverse effects, such as dryness of mouth, accommodation difficulties, conjunctival irritation, reduced sweating, dysphagia, heartburn, constipation, bladder voiding difficulties and dryness of nasal mucosa. In BT-B the relationship between autonomic and motor effects known from BT-A is substantially shifted towards autonomic effects. BT-B, therefore, should be used carefully in patients with autonomic disorders and in patients with concomitant anticholinergic therapy.
If NeuroBloc®/MyoBloc™ is used to treat cervical dystonia patients with antibody-induced failure of BT-A therapy, 86% of those will develop complete secondary therapy failure after five applications. If NeuroBloc®/ MyoBloc™ used to treat cervical dystonia patients without prior exposure to BT, 44% of those will develop complete secondary therapy failure after nine applications. NeuroBloc®/MyoBloc™, therefore, is associated with substantial antigenicity problems originating from a particular low specific biological potency. Systemic anticholinergic adverse effects and high antigenicity limits the clinical use of NeuroBloc®/ MyoBloc™ considerably.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baumann LS and ML Halem (2003) Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis.Arch. Dermatol. 139, 226–227.
Baumann L, A Slezinger, M Halem, J Vujevich, K Mallin, C Charles, LK Martin, L Black and J Bryde (2005) Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.Dermatol. Surg. 31, 263–270.
Benecke R, WH Jost, P Kanovsky, E Ruzicka, G Comes and S Grafe (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.Neurology 64(11), 1949–1951.
Brashear A, AL McAfee, ER Kuhn and WT Ambrosius (2003) Treatment with botulinum toxin type B for upper-limb spasticity.Arch. Phys. Med. Rehabil. 84, 103–107.
Brashear A, MF Lew, DD Dykstra, CL Comella, SA Factor, RL Rodnitzky, R Trosch, C Singer, MF Brin, JJ Murray, JD Wallace, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.Neurology 53, 1439–1446.
Brashear A, AL McAfee, ER Kuhn and WT Ambrosius (2003) Treatment with botulinum toxin type B for upper-limb spasticity.Arch. Phys. Med. Rehabil. 84, 103–107.
Brin MF, MF Lew, CH Adler, CL Comella, SA Factor, J Jankovic, C O’Brien, JJ Murray, JD Wallac, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 53, 1431–1438.
Comella CL, J Jankovic, KM Shannon, J Tsui, S Swenson, M Leurgans, W Fan, Dystonia Study Group (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 65, 1423–1429.
Consky ES, A Basinski, L Belle, R Ranawaya and AE Lang (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), assessment of validity and inter-rater reliability.Neurology 40 (suppl. 1), 445
Dressler D (2003) Botulinum toxin B bei Kindern mit spastischen Bewegungsstörungen und funktioneller Hypersalivation.Akt. Neurol. 30, 470.
Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.Mov. Disord. Suppl.8, S92-S100
Dressler D and R Benecke (2002) [Initial experiences with clinical use of botulinum toxin type B].Nervenarzt 73, 194–198.
Dressler D and R Benecke (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.Eur. Neurol. 49, 34–38.
Dressler D and H Bigalke (2005) Botulinum toxin type Bde novo therapy of cervical dystonia, frequency of antibody-induced therapy failure.J. Neurol. 252, 904–907
Dressler D and M Hallett (2006) Immunological aspects of Botox®, Dysport®, and NeuroBloc®/MyoBloc™.Eur. J. Neurol. 13 Suppl.1, 11–15.
Dressler D, F Adib Saberi and R Benecke (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis.J. Neurol. 249, 1729–1732.
Dressler D, R Benecke and H Bigalke (2003) Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure.J. Neurol. 250, 967–969
Dykstra D, A Enriquez and M Valley (2003) Treatment of overactive bladder with botulinum toxin type B, a pilot study.Int. Urogynecol. J. Pelvic Floor Dysfunct. 14, 424–426.
Fadeyi MO and QM Adams (2002) Use of botulinum toxin type B for migraine and tension headaches.Am. J. Health Syst. Pharm. 59, 1860–1862.
Health & Human Services, Public Health Service, Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Clinical Trial Design and Analysis. MyoBloc, Summary Basis of Approval Cervical Dystonia. Supplemental Clinical Review. 2000. Available from US Government through Freedom of Information (http, //www.fda.gov/cder/biologics/ products/botelan120800.htm
Jost WH (2001) Botulinum toxin type B in the treatment of anal fissures, first preliminary results.Dis. Colon Rectum 44, 1721–1722.
Kim EJ, AL Ramirez, JB Reeck and CS Maas (2003) The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.Plast. Reconstr. Surg. 112 (Suppl.), 88S-93S.
Lang AM (2004) Botulinum toxin type B in piriformis syndrome.Am. J. Phys. Med. Rehabil. 83, 198–202.
Oechsner M (2002) [Treatment of hip adductor spasticity with botulinum toxin type B].Nervenarzt. 73, 1179–1182.
Racette BA, L Good, S Sagitto and JS Perlmutter (2003) Botulinum toxin B reduces sialorrhea in parkinsonism.Mov. Disord. 18, 1059–1061.
Sataloff RT, YD Heman-Ackah, LL Simpson, JB Park, A Zwislewski, C Sokolow and S Mandel (2002) Botulinum toxin type B for treatment of spasmodic dysphonia, a case report.J. Voice. 16, 322–324.
Schwerin A, S Berweck, UM Fietzek and F Heinen (2004) Botulinum toxin B treatment in children with spastic movement disorders, a pilot study.Pediatr. Neurol. 31, 109–113.
Tousi B, JS Perumal, K Ahuja, A Ahmed and T Subramanian (2004) Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm.Parkinsonism Relat. Disord. 10, 455–456.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dressler, D., Eleopra, R. Clinical use of non-a botulinum toxins: botulinum toxin type B. neurotox res 9, 121–125 (2006). https://doi.org/10.1007/BF03033929
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03033929